Citigroup Portfolio holdings
Citigroup Inc., formed in 1998 through the landmark merger of Citicorp and Travelers Group, with roots tracing back to the 1812 founding of City Bank of New York, is a global financial powerhouse headquartered in New York City, managing trillions in assets. Operating in over 160 countries, Citigroup offers a broad spectrum of services, including consumer banking (via Citibank), investment banking, wealth management, and trading, serving millions of retail customers and major corporations, governments, and institutions worldwide. Under CEO Jane Fraser since 2021—the first woman to lead a major U.S. bank—Citigroup has focused on streamlining operations, exiting consumer banking in 13 markets to bolster its institutional and wealth management focus, while navigating post-2008 regulatory scrutiny and fines. Known for its vast global footprint and resilience through crises, Citigroup remains a key player in international finance, blending retail accessibility with high-stakes capital markets expertise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bank of America
BAC
|
+$349M |
| 2 |
Vanguard S&P 500 ETF
VOO
|
+$305M |
| 3 |
iShares Gold Trust
IAU
|
+$282M |
| 4 |
State Street SPDR S&P Regional Banking ETF
KRE
|
+$269M |
| 5 |
Blackrock
BLK
|
+$267M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$625M |
| 2 |
NVIDIA
NVDA
|
+$604M |
| 3 |
Tesla
TSLA
|
+$576M |
| 4 |
Microsoft
MSFT
|
+$552M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$357M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 40.73% |
| 2 | Technology | 20.55% |
| 3 | Financials | 7.82% |
| 4 | Consumer Discretionary | 7.64% |
| 5 | Communication Services | 5.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
IBO
5076
Impact BioMedical
IBO
$25.2M
| $5.68K | ﹤0.01% |
+696
| New | +$4.93K |
2025 Q2
0 quarters
|
|
5077
Seanergy Maritime Holdings
SHIP
$334M
| $5.65K | ﹤0.01% |
+896
| New | +$5.39K |
2025 Q2
0 quarters
|
|
5078
CALL
Zeo Energy Corp Warrants
ZEOWW
$155K
| $5.65K | ﹤0.01% |
88,458
| – | – |
2022 Q1
13 quarters
|
|
5079
Mercer International
MERC
$12.4M
| $5.65K | ﹤0.01% |
1,613
| – | – |
2013 Q2
48 quarters
|
|
5080
Invesco Dorsey Wright SmallCap Momentum ETF
DWAS
$377M
| $5.6K | ﹤0.01% |
66
| – | – |
2013 Q4
46 quarters
|
|
5081
DELISTED
Inozyme Pharma
INZY
| $5.56K | ﹤0.01% |
1,390
-36,748
| -96% | -$91K |
2023 Q2
8 quarters
|
|
5082
State Street SPDR Portfolio S&P 1500 Composite Stock Market ETF
SPTM
$14B
| $5.47K | ﹤0.01% |
+73
| New | +$5.07K |
2025 Q2
0 quarters
|
|
5083
DELISTED
ModivCare
MODV
| $5.4K | ﹤0.01% |
1,732
-5,797
| -77% | -$10.7K |
2013 Q2
48 quarters
|
|
5084
CALL
Tevogen Inc Warrant
TVGNW
$1.17M
| $5.39K | ﹤0.01% |
+77,151
| New | +$4.28K |
2025 Q2
0 quarters
|
|
5085
Artiva Biotherapeutics
ARTV
$288M
| $5.39K | ﹤0.01% |
3,567
-10,771
| -75% | -$22.6K |
2024 Q3
3 quarters
|
|
5086
Twin Vee PowerCats
VEEE
$5.73M
| $5.38K | ﹤0.01% |
+65
| New | +$6.3K |
2025 Q2
0 quarters
|
|
5087
Verde Clean Fuels
VGAS
$22M
| $5.31K | ﹤0.01% |
1,543
-866
| -36% | -$2.95K |
2023 Q1
9 quarters
|
|
5088
Decoy Therapeutics
DCOY
$760K
| $5.28K | ﹤0.01% |
+33
| New | +$4.64K |
2025 Q2
0 quarters
|
|
5089
First Trust Small Cap Growth AlphaDEX Fund
FYC
$1.71B
| $5.17K | ﹤0.01% |
65
| – | – |
2024 Q4
2 quarters
|
|
5090
Studio City International Holdings
MSC
$192M
| $5.17K | ﹤0.01% |
1,629
| – | – |
2018 Q4
26 quarters
|
|
5091
BioVie
BIVI
$10.1M
| $5.1K | ﹤0.01% |
+551
| New | +$5.44K |
2024 Q4
2 quarters
|
|
5092
Alto Neuroscience
ANRO
$872M
| $5.07K | ﹤0.01% |
2,303
-12,841
| -85% | -$30.6K |
2024 Q1
5 quarters
|
|
5093
Banco Macro
BMA
$4.06B
| $5.05K | ﹤0.01% |
72
-253
| -78% | -$20.9K |
2024 Q4
2 quarters
|
|
5094
CALL
Core Scientific Inc Tranche 1 Warrants
CORZW
$675M
| $5.03K | ﹤0.01% |
464
| – | – |
2024 Q1
5 quarters
|
|
5095
Invesco CEF Income Composite ETF
PCEF
$753M
| $5K | ﹤0.01% |
256
| – | – |
2024 Q1
5 quarters
|
|
5096
OneMedNet
ONMD
$26.7M
| $4.97K | ﹤0.01% |
+872
| New | +$3.8K |
2025 Q2
0 quarters
|
|
5097
DELISTED
Elevation Oncology
ELEV
| $4.93K | ﹤0.01% |
13,442
-66,526
| -83% | -$22.2K |
2024 Q1
5 quarters
|
|
5098
i-80 Gold Corp
IAUX
$1.32B
| $4.92K | ﹤0.01% |
7,986
-216,022
| -96% | -$127K |
2022 Q2
12 quarters
|
|
5099
Ring Energy
REI
$344M
| $4.89K | ﹤0.01% |
6,164
-100,616
| -94% | -$85.2K |
2018 Q3
27 quarters
|
|
5100
Lifetime Brands
LCUT
$190M
| $4.76K | ﹤0.01% |
934
-7,759
| -89% | -$28.9K |
2023 Q4
6 quarters
|
|
Similar funds
Citigroup's Q2 2025 Portfolio in Review
As of Q2 2025, Citigroup held 6,003 positions worth $204B, up 4.1% from $196B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Citigroup's Q2 2025 filing shows 467 new, 1,653 increased, 2,974 reduced and 377 closed positions. Its largest new stake was Amrize Ltd: 2,294,135 shares worth $114M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $625M.
By sector, the portfolio is most concentrated in Miscellaneous at 41% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
- Citigroup's largest Q2 2025 buy was Amrize Ltd: 2,294,135 shares worth $114M.
- Citigroup added most to Bank of America in Q2 2025, an estimated $349M increase.
- Citigroup's biggest Q2 2025 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $625M.
- Citigroup fully exited James Hardie Industries in Q2 2025, selling an estimated $125M.
- Citigroup's ten largest holdings make up 20% of its $204B portfolio in Q2 2025.
- Citigroup opened 467 new positions and closed 377 in Q2 2025.
- Citigroup's portfolio value rose 4.1% quarter-over-quarter to $204B.
Based on Citigroup's 13F filing for Q2 2025, filed 11 Aug 2025.